- Poster presentation
- Open Access
Epitope-optimization creates highly immunogenic alpha fetoprotein antigen to break immune tolerance and potently activates CD8 T cells to prevents autochthonous hepatocellular carcinoma
© Hong et al; licensee BioMed Central Ltd. 2013
- Published: 7 November 2013
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
- Tumor Cell
- Hepatocellular Carcinoma
- Good Chance
- Immune Tolerance
In this study, we investigated whether mouse alpha fetoprotein (mAFP), the shared self/tumor antigen of hepatocellular carcinoma (HCC), could be rationally engineered to create effective vaccine to break tolerance and potently activate CD8 T cells to prevent clinically-relevant carcinogen-induced autochthonous HCC. We found that the computer-guided epitope-optimization created optimized opt-mAFP and that immunization with lentivector (lv) expressing opt-mAFP, but not wt-mAFP, potently activated CD8 cells specific for three novel H-2b restricted CD8 epitopes, which cross-recognized wt-mAFP epitopes naturally processed and presented by wt-mAFP+ tumor cells. Immunization with opt-mAFP-lv, but not wt-mAFP-lv, completely protected mice from wt-mAFP+ tumor challenge and effectively prevented carcinogen-induced autochthonous HCC. Prime-boost with opt-mAFP-lv and vaccinia vector opt-mAFP-vv significantly increased the wt-mAFP-specific CD8 T cells that were highly responsive to emerging HCC tumor cells in the liver, enhancing prevention of autochthonous HCC. Our data demonstrate that epitope-optimization creates immunogenic opt-mAFP that is able to break tolerance and activate potent CD8 responses, which can cross-recognize wt-mAFP peptides, but also recognize and kill mAFP+ tumor cells. Our study provides a practical roadmap to develop effective human vaccines that should have a better chance of success than the current human HCC vaccines based on native wt-AFP.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.